Clinical trial
Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive…
NCT00128635 · Abramson Cancer Center at Penn Medicine, Other · Completed
Key facts
| NCT number | NCT00128635 |
|---|---|
| Title | Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme |
| Official title | An Open-Label, Dose Confirmation and Dosimetry Study of Interstitial 131 I-chTNT-1/B MAb (COTARA(TM)) For the Treatment of Glioblastoma Multiforme (GBM) at 1st or 2nd Relapse |
| Lead sponsor | Abramson Cancer Center at Penn Medicine, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Radiation |
| Interventions | iodine I 131 monoclonal antibody TNT-1/B |
| Enrollment | 22 |
| Start date | Oct 1, 2005 |
| Completion | Oct 1, 2007 |
| First posted | Aug 10, 2005 |
| Last update posted | Feb 19, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: